Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
CAR T-cell therapy
NGS (Next-Generation Sequencing)
PET/CT 18F-FDG
ctDNA (circulating tumor DNA)
follicular lymphoma
minimal residual disease
monitoring
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
12
2023
accepted:
21
12
2023
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
25
1
2024
Statut:
epublish
Résumé
[This corrects the article DOI: 10.3389/fimmu.2023.1188818.].
Identifiants
pubmed: 38268917
doi: 10.3389/fimmu.2023.1349296
pmc: PMC10806392
doi:
Types de publication
Published Erratum
Langues
eng
Sous-ensembles de citation
IM
Pagination
1349296Commentaires et corrections
Type : ErratumFor
Informations de copyright
Copyright © 2024 Jiménez-Ubieto, Martín-Muñoz, Poza, Dorado, García-Ortiz, Revilla, Sarandeses, Ruiz-Heredia, Baumann, Rodríguez, Calbacho, Sánchez, Pina, García-Sancho, Figaredo, Gil-Alós, Rufián, Rodríguez, Carneros, Martínez-Laperche, Bastos-Oreiro, Wang, Cedena, Rapado, de Toledo, Gallardo, Valeri, Ayala, Martínez-López and Barrio.